Free Trial
NASDAQ:VERU

Veru Q4 2026 Earnings Date & Estimates

Veru logo
$2.08 -0.02 (-0.72%)
As of 02:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Veru is estimated to report Q4 2026 earnings on Thursday, November 26, 2026, before market opens.

Upcoming Earnings Announcement

Quarter
Q4 2026
Announcement Date
Time
Before Market Opens

What Analysts Expect from Veru in Q4 2026

Veru is expected to post earnings of -$0.2533 per share. Veru last reported on August 10, 2026, posting -$0.30 per share and beating the -$0.32 consensus estimate. Veru has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.2533

Recent Track Record

Last Reported
Q3 2026
Last Quarter EPS
-$0.30 (Beat by +$0.02)
EPS Beat Rate
7 of last 8 quarters

Veru Q4 2026 Earnings FAQ

Veru (NASDAQ:VERU) is estimated to report Q4 2026 earnings on Thursday, November 26, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Veru's Q4 2026 earnings conference call is scheduled for Friday, December 18, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Veru to post earnings of -$0.2533 per share for Q4 2026.

Veru Earnings Headlines

Veru (NASDAQ:VERU) Upgraded at Wall Street Zen
Management just bought 2.8 million shares
Management just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 in one quarter. Institutions own about 83% of shares, including BlackRock's 32 million shares worth $716 million and Vanguard's 48 million shares worth nearly $1.1 billion. A new multi-year deal with Palantir adds an AI-driven edge to this energy producer's operations.tc pixel
Veru (NASDAQ:VERU) Rating Lowered to Strong Sell at Wall Street Zen
See More Veru Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Veru? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Veru and other key companies, straight to your email.

About Veru

Veru (NASDAQ:VERU) is a biopharmaceutical company focused on developing medicines for metabolic diseases and cancer. Its research programs include enobosarm, which is being studied to help preserve muscle during weight loss associated with GLP-1 medicines, as well as candidates investigated for breast and prostate cancer.

The company has also developed sabizabulin, an investigational drug studied for cancer treatment. These medicines remain development-stage products; Veru’s clinical programs and priorities may change as research progresses.

Historically, Veru was known as The Female Health Company and developed FC2, a female condom distributed in the United States and internationally. The company adopted the Veru name in 2017 as it expanded its focus into pharmaceuticals.

View Veru Profile